- Location
biopharmaceutical company
"-
Purified Cannabinoid Is Effective in Treating Severe Forms of Childhood Epilepsy
Feb 25, 2014A new international multi-center study led by researchers from UCSF Benioff Children's Hospital is the first to evaluate whether purified cannabinoid is effective in treating severe forms of childhood epilepsy that do not respond to ...
-
A Study Is The First to Evaluate Whether Purified Purified Cannabinoid Is Effective
Feb 14, 2014A new international multi-center study led by researchers from UCSF Benioff Children's Hospital is the first to evaluate whether purified cannabinoid is effective in treating severe forms of childhood epilepsy that do not respond to ...
-
TM Platform Will Be Used to Screen for GPCR-Directed Allosteric Modulator Antibodies
Feb 14, 2014DTect-All(TM) platform will be used to screen for GPCR-directed allosteric modulator antibodies Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G ...
Tags: DTect-All(TM)
-
Soligenix Announced Significant Steps Forward in The Development of ThermoVax
Jan 17, 2014Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, ...
Tags: Soligenix, NIAID, ThermoVax, Drs.John Carpenter
-
Sutro Biopharma Has Entered Into a Collaboration Agreement
Jan 8, 2014Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration ...
Tags: Bispecific Antibodies, Sutro's Cell-Free Protein Synthesis Technology
-
The European Commission Has Granted Orphan Drug Designation to Natpara?
Jan 6, 2014NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Commission has granted orphan drug ...
-
Cerenis Therapeutics Did Not Reach Its Primary Endpoint in Post-ACS Patients
Jan 3, 2014Cerenis Therapeutics, the biopharmaceutical company, today announced that its Phase IIb CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis REgression) study did not reach its primary endpoint in post-Acute Coronary Syndrome ...
Tags: Cerenis Therapeutics, Phase IIb CHI-SQUARE, post-Acute Coronary Syndrome
-
Ocera Therapeutics Has Entered Into a Technology Transfer and License Pact with Roche
Dec 19, 2013Ocera Therapeutics (Nasdaq:OCRX) today announced that it has entered into a Technology Transfer and License Agreement with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its ...
Tags: Ocera Therapeutics, Roche, Macrocyclic Template Chemistry
-
Ono Pharmaceuticals Has Elected to Amend and Expand The Existing Collaboration Agreement
Dec 12, 2013Receptos, a biopharmaceutical company, has announced that Ono Pharmaceuticals has elected to amend and expand the existing collaboration agreement between the parties to include transfer to Ono of the Receptos G-protein-coupled receptor ...
Tags: Pharmaceuticals, Receptos
-
Auxilium Pharmaceuticals, a Biopharmaceutical Company, Has Obtained an Approval
Dec 10, 2013Auxilium Pharmaceuticals, a biopharmaceutical company, has obtained an approval from the US Food and Drug Administration (FDA) for Xiaflex (collagenase clostridium histolyticum) for the treatment of Peyronie's disease. The company claims ...
Tags: Peyronie's Disease Drug, Medicine
-
InnaVirVax Has Commenced a Phase II Clinical Trial of The VAC-3S Vaccine
Dec 5, 2013InnaVirVax, a biopharmaceutical company, has commenced a Phase II clinical trial evaluating the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy (ART) in the course of HIV-1 infection. The ...
-
Agalimmune Has Been Created to Develop Innovative Immunotherapeutics
Nov 29, 2013Agalimmune, a biopharmaceutical company, has been created to develop innovative immunotherapeutics for the treatment of cancer, with a focus on solid tumours. The new company has been founded by an investment group comprising Loxbridge ...
Tags: solid tumours, cancer treatment
-
Signum Dermalogix Grant Totaling $1.6m for The Development of a Topical Drug Candidate
Nov 18, 2013Signum Dermalogix, a biopharmaceutical company, has announced that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the company a Small Business Innovation Research (SBIR) Phase II grant totaling ...
-
Sorrento Therapeutics Announced a Definitive Agreement to Acquire Concortis Biosystems
Nov 18, 2013Sorrento Therapeutics, a clinical-stage biopharmaceutical company, has announced a definitive agreement to acquire US-based Concortis Biosystems. This acquisition provides Sorrento Therapeutics with a comprehensive technology platform for ...
-
Stemline Therapeutics Announce Their Collaboration to Accelerate The Development of SL-401
Oct 31, 2013Stemline Therapeutics, a clinical stage biopharmaceutical company, and The Leukemia & Lymphoma Society (LLS), a voluntary health organization, have announced their collaboration to accelerate the development of SL-401 for the treatment of ...
Related Products
-
Single-Molecule Analysis Protein, Molecule, and Cell Engineering Detection System
-
Openflex Digital Single Molecule Detection System Jx-1g
-
Single Molecule Detection of Proteins in Single Cells
-
CAS-Envision Single Molecule Fluorescence Immunoanalyzer
-
Single Molecule Fluorescence Immunoanalyzer
-
High-Resolution Molecular Detection Device
